New Zealand markets closed

Shanghai Junshi Biosciences Co., Ltd. (1877.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
9.780+0.070 (+0.72%)
As of 02:49PM HKT. Market open.

Shanghai Junshi Biosciences Co., Ltd.

Building 7
15th Floor No.6, Lane 100, Pingjiaqiao Road Pudong New Area
Shanghai 200126
86 21 6105 8800

Full-time employees2,568

Key executives

NameTitlePayExercisedYear born
Mr. Jun XiongExecutive ChairmanN/AN/A1974
Mr. Cong LiCo-CEO & Executive DirectorN/AN/A1964
Dr. Jianjun ZouGM, CEO & Executive DirectorN/AN/A1972
Mr. Baohong XuFinancial DirectorN/AN/A1979
Mr. Zhuobing ZhangDeputy GM & Executive DirectorN/AN/A1968
Dr. Sheng Yao Ph.D.Senior VP & Executive DirectorN/AN/A1976
Dr. Gang WangExecutive Director, Chief Quality Officer & Senior VP of Industry AffairsN/AN/A1957
Ms. Yingge ChenJoint Company SecretaryN/AN/A1992
Ms. Lu YuanAssistant to GM & Chief of Internal Audit DepartmentN/AN/A1982
Mr. Qian WeiChief Commercial OfficerN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.


Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

Corporate governance

Shanghai Junshi Biosciences Co., Ltd.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.